BCL2 and lymphoma: The first developed compound ABT-737, targeting BCL-2, BCL-XL and BCL-W, exhibited single-agent antitumor activity in preclinical models of lymphoma and small-cell lung cancer (SCLC), as well as in primary patient-derived CLL samples [94].